Bulletin from ExpreS2ion's extraordinary general meeting on 23 March 2023
Helsingborg, Sweden, 23 March 2023 – ExpreS2ion Biotech Holding AB's (“ExpreS2ion” or the “Company”) extraordinary general meeting took place today. The extraordinary general meeting resolved to approve the Board of Directors' resolution to carry out a new issue of units consisting of shares and warrants of series TO 8 ("Units") with preferential rights for the ExpreS2ion’s existing shareholders (the “Rights Issue”).Approval of the Board of Directors' resolution on the Rights Issue The extraordinary general meeting resolved, in accordance with the Board of Directors’ proposal, to approve